Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure
Damien Logeart, MD*,*,
Gabriel Thabut, MD ,
Patrick Jourdain, MD ,
Christophe Chavelas, MD*,
Pascale Beyne, PhD ,
Florence Beauvais, MD*,
Erik Bouvier, MD* and
Alain Cohen Solal, MD, PhD*
* Service de Cardiologie, Hôpital Beaujon, Clichy, France
Service de Pneumologie, Hôpital Beaujon, Clichy, France
Laboratoire de Biochimie, Hôpital Beaujon, Clichy, France
Service de Cardiologie, Hôpital René Dubos, Pontoise, France

View larger version (13K):
[in a new window]
|
Figure 1 Box plots showing median predischarge levels of B-type natriuretic peptide (BNP) from admission to discharge (derivation study). Mean levels are indicated in the box.
|
|

View larger version (14K):
[in a new window]
|
Figure 2 Receiver operating characteristic (ROC) curve for predischarge B-type natriuretic peptide (BNP) cut-off values and association with death or re-admission at six months (derivation study).
|
|

View larger version (13K):
[in a new window]
|
Figure 3 Kaplan-Meier curves showing the cumulative incidence of death or re-admission according to predischarge B-type natriuretic peptide (BNP) cut-off value of 350 ng/l in the validation study; p = 0.0001.
|
|

View larger version (18K):
[in a new window]
|
Figure 4 Kaplan-Meier curves showing the cumulative incidence of death or re-admission according to predischarge B-type natriuretic peptide (BNP) ranges (<350, 350 to 700, >700 ng/l) in the whole population; p < 0.001 for the trend among BNP ranges. On the right, hazard ratios are shown for each BNP range.
|
|
|